Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 in primary or TRPC6 genetic focal segmental glomerulosclerosis
jRCT2031250735Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing BI 764198 treatment with Placebo treatment (2 arms). Primary endpoint: Relative change in 24-hour UPCR from baseline to Week 104. Started Apr 2026; status: recruiting.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on jRCT2031250735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250735.